Immunome Inc (IMNM) — Financial Flexibility Index

Latest as of December 2025: -0.90x

Immunome Inc (IMNM) has a Financial Flexibility Index of -0.90x as of December 2025. Free cash flow of $-43.95 Million (operating CF $-47.95 Million minus capex $4.00 Million) represents -1% of total liabilities ($48.84 Million). Also explore IMNM shareholders equity momentum to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.90x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-43.95 Million
Operating CF − Capex

Total Liabilities

$48.84 Million
USD

Capital Expenditures

$4.00 Million
USD

Immunome Inc Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Immunome Inc across 8 annual periods. Check IMNM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Immunome Inc (2018–2025)

Year-by-year free cash flow to debt coverage for Immunome Inc. For the full company profile including market capitalisation, see Immunome Inc (IMNM) market capitalisation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -3.71x $-181.23 Million $-190.92 Million $48.84 Million ▼ -282.6%
2024 -0.97x $-57.29 Million $-110.79 Million $59.08 Million ▼ -312.5%
2023 -0.24x $-6.74 Million $-7.57 Million $28.66 Million ▲ +93.9%
2022 -3.85x $-28.44 Million $-28.69 Million $7.39 Million ▼ -106.5%
2021 -1.86x $-18.15 Million $-18.23 Million $9.74 Million ▲ +48.7%
2020 -3.63x $-11.55 Million $-12.13 Million $3.18 Million ▼ -1477.5%
2019 -0.23x $-9.37 Million $-9.60 Million $40.69 Million ▲ +4.9%
2018 -0.24x $-7.18 Million $-7.41 Million $29.65 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities